Careers  |   Log In  |   Register  |   Welcome Center  |   Follow Us  Facebook  Twitter Google Plus

Combination Immunotherapy May Be Viable Bladder Cancer Treatment Option

Newly approved combination immunotherapy treatments show promise for treating progressive bladder cancer. Early results from phase 1 and 2 trials show that combination treatment with cabozantinib, nivolumab, and ipilimumab was well-tolerated, safe, and showed high activity in 30% of treated patients. Furthermore, a sub-group of patients demonstrated an encouraging response rate of 44% when treated with dual cabozantinib and nivolumab therapy alone. In addition to this, avelumab is currently undergoing a phase 3 trial in metastatic bladder cancer patients who previously responded to chemotherapy.

References:

Welch A. Apolo Discusses Promising Immunotherapy Combos in Bladder Cancer. Oncology website. http://www.targetedonc.com/news/apolo-discusses-promising-immunotherapy-combos-in-bladder-cancer. Published 6 March 2017.

Apolo A, Mortazavi A, Stein MN, et al. A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. J Clin Oncol. 2017;35 (suppl 6S; abstract 293).

Patel MR, Ellerton JA, Infante JR, et al. Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial. J Clin Oncol. 2017;35 (suppl 6S; abstract 330).